Abbvie Inc ABBV

$285.64 +0.45 (0.16%)

Valuation

Market cap
504,666,752,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
26.24
Forward PE
20.48
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,631,800
Avg volume
4,659,582
Day's range
$282.30 – $286.77
Shares out
1,766,793,000
Stochastic %K
67%
Beta
0.24
Analysts
Strong Sell
Price target
$284.40

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Quantumup Oct 26, 1:27 PM
Guggenheim reiterated $ORKA Buy-$200 after the Co. announced 16-week interim data from the Ph IIb EVERLAST-B study (n = 187) of ORKA-001 (ultra-long-acting anti-IL-23p19 mAb) in psoriasis (PSO). UCBJY $ABBV PTGX $JNJ APGE SYRE ABVX NVS LLY BMY TAK Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2114709980477587837?s=20
0 replies
JFais Oct 26, 12:22 PM
Between $GMAB, $ZYME, $CORT ( $IMGN/ $ABBV not to be forgotten as well for paving the way), the list goes on Crazy amount of competition in the ovarian cancer space (but exciting time for patients!)
1 replies
Stocktradesmoon Oct 26, 10:08 AM
$ABCL 👏 $MRNA $PFE $SLS $ABBV
2 replies
55X_ROI_Q1_2026 Oct 26, 3:05 AM
$SLS VIALE-M a massive P3 conducted by $ABBV for AML Cr1, transplant ineligible First Remission patients, a dire and existential threat to Gps in CR2… $MRNA
2 replies
TopOptionAlert Oct 25, 11:58 PM
$ABBV NOV20 295C · still actionable Zone: $283.64 to $287.64 Invalidation: close under $280 Objectives: $291.40, then $300 The math: up 2.0% to the first objective and 5.0% to the second, against 2.0% risk on the invalidation, better than 2.5 to 1 to the second. Dear friend, picture a steady swing setup on a name that has quietly climbed all year and is now sitting just under its highest price in a year. AbbVie closed Friday at 285 dollars and 64 cents, up a little on the day, after holding the 282 dollar area twice in the past week. What that means is simple. Buyers keep showing up near that floor, and with results due October 30, there is a clear date for the next push toward 291 dollars and then 300 dollars if that floor keeps holding. P.S. Watch 282 dollars and 30 cents on any dip. That was the low on Friday, and holding it keeps this climb intact.
0 replies
thatsolardude365 Oct 25, 11:18 PM
$ABBV: one word is missing in Garcia: granuloma appears nowhere in Juvederm's warnings, glossary or website, the complaint alleges, even though the lumps can surface years later. Nothing to claim. Open Class Actions.
0 replies
seasonal13 Oct 24, 10:45 PM
$ABBV over 300 Monday.
1 replies
thatsolardude365 Oct 24, 7:08 PM
$ABBV: the study behind the Juvederm suit found delayed nodules in 0.5% to 0.98% of cases, higher than other fillers. Plaintiffs allege labeling calls nodules a 1-month issue, not a granuloma risk. Nothing to claim. Open Class Actions.
0 replies